Our results showed that the killing of Vγ9Vδ2 T cells against primary glioma cells was significantly enhanced after ZOL (Fig. 3A) or BTN3A1 agonistic antibody stimulation (Fig. 3B). The gene discussed is BTN3A1; the disease is central nervous system cancer.